Glaxosmithkline Share News (GSK)

Glaxo Notes Positive Phase III Data For Asthma Treatment Mepolizumab

Cost a focus as GSK takes lead in new wave of biotech lung drugs

* GSK drug ahead of similar ones from Teva and AstraZeneca * Under-the-skin injection set for filing this year * Data on GSK's mepolizumab presented at Munich congress * NEJM editorial questions cost-effectiveness of new drugs By Ben Hirschler LONDON, Sept 8 (Reuters

London midday: UK stocks sink on fears over Scottish referendum, Ukraine

Concerns surrounding the upcoming referendum on Scottish independence and a fragile ceasefire agreement in Ukraine were weighing heavily on UK stocks on Monday. London's FTSE 100 was trading down 1% at 6,789 by midday. The index has not closed below the 6,800 mark since 22 August when it settled at

Glaxo Presents Data From Blood Eosinophil Levels Studies

BUZZ-U.S. Stocks on the Move-Keryx, GlaxoSmithKline, Astrazeneca

(For faster updates on individual market-movers, Eikon users please use search string "STXBZ US"; for more market insights, including options activity, ; for the Day Ahead newsletter, http://link.reuters.com/mex49s; for the Morning News Call newsletter, http://link.reuters.com/nex49s) U.S. stock

UK BROKER RATINGS: Bernstein Raises Tesco And Cuts Morrisons

AstraZeneca drug misses goal in severe COPD but improves lung function

LONDON, Sept 8 (Reuters) - An experimental drug from AstraZeneca - part of a new wave of injectable respiratory drugs designed for people who do not respond adequately to traditional inhalers - has shown mixed results in chronic lung disease. Data published in The Lancet on Monday and being

Experimental Ebola vaccine protects monkeys for 10 months

By Sharon Begley NEW YORK, Sept 7 (Reuters) - An experimental Ebola vaccine similar to one being developed by GlaxoSmithKline is effective for at least five weeks in lab monkeys but requires boosting with an additional vaccine to extend its protection to 10 months, according to a study publ

WHO urges use of blood-derived drugs against Ebola, backs vaccine trials

GENEVA, Sept 5 (Reuters) - The World Health Organisation (WHO) said on Friday that experts had agreed that blood-derived drug therapies and convalescent serum may be used for treatment of Ebola virus, and called for investment in the unproven drugs. Two "promising" Ebola vaccines have also

Drug and vaccine makers in race against Ebola

* Clinical trials to test safety, efficacy of treatments * ZMapp president expects human trials to begin in 2015 * GSK vaccine clinical trials under way, data by year-end By Stephanie Nebehay GENEVA, Sept 5 (Reuters) - Drug and vaccine companies are racing to conduct clini

Ebola Vaccine Trials Underway

WHO urges drug companies, regulators to speed Ebola work

* WHO hosts two-day talks on experimental Ebola therapies * Says eight drugs and two vaccines have shown potential * Calls for speeding work on developing safe, efficient treatments * A few hundred doses of ZMapp may be available by year-end * Newlink gets FDA nod for clin

BUZZ-U.S. Stocks on the Move-Ciena, Matrix, Methode, Mitek

(For faster updates on individual market-movers, Eikon users please use search string "STXBZ US"; for more market insights, including options activity, ; for the Day Ahead newsletter, http://link.reuters.com/mex49s; for the Morning News Call newsletter, http://link.reuters.com/nex49s) U.S.

BUZZ-U.S. Stocks on the Move-Kamada, Mitek, Stereotaxis, Shoe Carnival

(For faster updates on individual market-movers, Eikon users please use search string "STXBZ US"; for more market insights, including options activity, ; for the Day Ahead newsletter, http://link.reuters.com/mex49s; for the Morning News Call newsletter, http://link.reuters.com/nex49s) U.S.

BUZZ-U.S. Stocks on the Move-Ciena, Mitek, GoPro, Memorial Production

(For faster updates on individual market-movers, Eikon users please use search string "STXBZ US"; for more market insights, including options activity, ; for the Day Ahead newsletter, http://link.reuters.com/mex49s; for the Morning News Call newsletter, http://link.reuters.com/nex49s) U.S.